SIRPA and cancer: Hazama et al. also developed a peptide-based macrocyclic peptide (c[Ac-DYRYSAVYSIHPSWC]G) inhibiting the interaction between cluster of differentiation 47 (CD47) of cancer cell and signal regulatory protein α (SIRPα) of macrophages and showed its in vivo efficacy [270].